No CrossRef data available.
Article contents
Nalmefene for daily consumption of alcohol
Published online by Cambridge University Press: 23 March 2020
Abstract
Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction
The level of high-risk alcohol consumption WHO is estimated at more than 40 mg for women and 60 mg for men.
Nalmefene is a new treatment that breaks the cycle of continued use of alcohol.
Methodology
A sample of 18 patients of a Mental Health Centre in the province of Leon alcohol dependent and high consumption They received nalmefene 18 mg daily continuous treatment for 6–9 months is selected. We appreciate the adherence of patients and the efficacy, tolerability and impact on physical health.
Results
We appreciate reduction in the amount of alcohol ingested observed by both the patient and their relatives without any cases of neglect and few side effects.
We got two patients leave the alcohol completely and an average decline in consumption over 9 Basic Units of Drink.* (90 g).
We observed improvement in the quality of life in patients with multiple pathologies and difficult social situation.
Disclosure of interest
The authors have not supplied their declaration of competing interest.
- Type
- EV115
- Information
- European Psychiatry , Volume 33 , Issue S1: Abstracts of the 24th European Congress of Psychiatry , March 2016 , pp. S320 - S321
- Copyright
- Copyright © European Psychiatric Association 2016
You have
Access
Comments
No Comments have been published for this article.